CAR-TCR Summit Europe 2018 London, England, UK 20-22 February 2018

Description:
CAR-TCR Summit Europe is the leading end-to-end summit focused on delivering safe, effective and commercially successful CAR and TCR cell therapies globally.

With the first CAR-T approved and the next poised to receive approval from the FDA and EMA by the end of 2017, CAR-T therapies aren't going anywhere and are set to become mainstream frontline cancer treatments.

As we see success, there are still two key areas even for the leaders to address: European regulations and global distribution. Alongside this, addressing the challenges with improving the underwhelming performance of CAR-TCR therapies in solid tumor indications are more important now than ever before.

URLs:
Booking: https://go.evvnt.com/169511-0
Brochure: https://go.evvnt.com/169511-1

Prices:
Gold: Conference + 2 Workshops: GBP 2497
Silver: Conference + 1 Workshop: GBP 2098
Bronze: Conference Only: GBP 1699
Workshop Only: GBP 499

Time: 8:00 am to 6:00 pm

Speakers: Jian Irish, SVP, Supply Chain, Kite Pharma, Lothar Germeroth, SVP, Managing Director, Juno Therapeutics, Isaac Ciechanover, CEO, Atara Biotherapeutics, Jens Hasskarl, Senior Director, Medical, Clinical Research And Development, Celgene, John Maher, CSO, Leucid Bio, Thierry Wurch, Director. Immuno-Oncology External Research And Innovation, Servier, Helen Tayton-Martin, CBO, Adaptimmune, Representative to be confirmed, Cellectis, Dolores Schendel, CEO, Medigene, Elisa Kieback, CEO, T-Knife, Michael Leek, CEO, TC Biopharm, Oezlem Anak, Senior Global Clinical Programme Head, Cell And Gene Therapies, Novartis